IgM型AL淀粉样变性:临床、基因组与骨髓形态学特征揭示疾病生物学及结局
本研究对比1174例新诊断AL淀粉样变性中75例(6%)IgM型与非IgM型患者,发现IgM型轻链水平更低、心脏及多器官受累较少、软组织及周围神经受累更多,t(11;14)较少见,MYD88L265P和CXCR4突变率分别为58%和17%。血液病理复核将IgM型分为纯浆细胞肿瘤(23%)和淋巴浆细胞肿瘤(63%),两亚型遗传学异常截然不同。IgM型AL按Mayo 2012分期分层总生存更短,可能与血液学缓解率较低有关。
要点
- IgM型AL淀粉样变性占6%,心脏和多器官受累较少,软组织及周围神经受累较多。
- IgM型AL中t(11;14)少见,MYD88L265P突变率58%,CXCR4突变率17%。
- IgM型AL可分为淋巴浆细胞肿瘤和纯浆细胞肿瘤两亚型,遗传学特征不同,治疗应针对克隆性疾病。
核心结论
- IgM型AL淀粉样变性具有独特的临床和遗传学特征,可分为淋巴浆细胞肿瘤和纯浆细胞肿瘤两个亚型,治疗决策应针对克隆性疾病。
研究设计与样本
- 研究纳入1174例新诊断AL淀粉样变性患者,其中IgM型75例(6%),对比IgM型与非IgM型患者的临床、基因组和骨髓形态学特征。
主要发现
- IgM型患者轻链水平较低(12.5 vs. 22.5 mg/dL;p < 0.001)。
- IgM型患者心脏受累较少(56% vs. 73%,p = 0.002),>1个器官受累较少(31% vs. 44%,p = 0.02),软组织及周围神经受累更多。
- IgM型患者t(11;14)较少见(27% vs. 50%,p = 0.008),MYD88L265P突变率为58%(29/50),CXCR4突变率为17%(8/46)。
- 血液病理复核显示IgM型中纯浆细胞肿瘤占23%(16/70),淋巴浆细胞肿瘤占63%(44/70),其他占14%。
- 淋巴浆细胞肿瘤与纯浆细胞肿瘤遗传学异常不同:t(11;14)为0%(0/18)vs. 60%(9/15),p < 0.001;MYD88L265P突变为84%(27/32)vs. 0%(0/14),p < 0.001;CXCR4突变为29%(8/28)vs. 0%(0/14),p = 0.04。
临床怎么用
- 对IgM型AL淀粉样变性应进行血液病理复核以区分淋巴浆细胞肿瘤和纯浆细胞肿瘤亚型,并据此选择针对克隆性疾病的治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study evaluates newly diagnosed IgM (6%, n = 75/1174) vs. non-IgM light chain amyloidosis patients. IgM amyloid patients had lower light chains (12.5 vs. 22.5 mg/dL; p < 0.001). Heart (56% vs. 73%, p = 0.002) and >1 organ involvement (31% vs. 44%, p = 0.02) was less common in IgM amyloidosis, while soft tissue and peripheral nerve involvement was more common. t(11;14) was less common (27% vs. 50%, p = 0.008) in IgM amyloidosis. Rates of MYD88L265P and CXCR4WHIM mutation in IgM amyloidosis were 58% (29/50) and 17% (8/46). Diagnosis after hematopathology review in IgM amyloidosis was pure plasma cell neoplasm (PPCN) in 23% (16/70), lymphoplasmacytic neoplasm (LPL) in 63% (44/70) patients, and other (14%). LPL vs. PPCN groups had distinct genetic abnormalities: t(11;14): 0% (0/18) vs. 60% (9/15), p < 0.001; MYD88L265P mutation: 84% (27/32) vs. 0% (0/14), p < 0.001; CXCR4 mutation: 29% (8/28) vs. 0% (0/14), p = 0.04. Overall survival was shorter in IgM AL when stratified by Mayo 2012 stage; stage 1/2 (59 vs. 125.9 months, p = 0.003) and stage 3/4 (6.5 vs. 12.9 months, p = 0.075), likely due to lower hematologic response rates (6 months: 39% vs. 59%, p = 0.008). We characterized two subtypes of IgM amyloidosis (LPL/PPCN). This can aid in therapeutic decision-making, with treatment directed at the clonal disease.
引用
- Sidana S, Larson DP, Greipp PT, et al. IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. Leukemia. 2019. PMID: 31780812. doi:10.1038/s41375-019-0667-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。